Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer

Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer

Conditions: Ovarian Cancer
Interventions: Drug: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Medical College of Wisconsin; The Cleveland Clinic; Merck Sharp & Dohme LLC
Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 27, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments